Jinxue Zhou

机构：Henan Cancer Hospital · ORCID：0000-0003-4852-6274

发表论文 40 篇 · 总被引 339 次 · h-index 11

代表论文

• Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients (2023 · Hepatology International · 被引 60)
• Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (2022 · Frontiers in Immunology · 被引 51)
• The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations (2022 · Journal of Hepatology · 被引 25)
• Textbook outcomes in liver surgery for gallbladder cancer patients treated with curative-intent resection: a multicenter observational study (2023 · International Journal of Surgery · 被引 23)
• The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy (2023 · Hepatology International · 被引 15)
• Idarubicin-loaded degradable hydrogel for TACE therapy enhances anti-tumor immunity in hepatocellular carcinoma (2024 · Materials Today Bio · 被引 14)